Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
04 October 2022 | Story Leonie Bolleurs | Photo Leonie Bolleurs
Matseliso Monnapula, Dr Jana Vermaas, and Liezl van der Walt
Matseliso Monnapula, Dr Jana Vermaas, and Liezl van der Walt. They are all involved in a research project to grow a new textile that resembles leather.

Pure curiosity. 

That was what gave rise to the development of a new textile, which was created in the Textile Lab and later evaluated for consumer use in the Sensory Lab of the University of the Free State (UFS).

Matseliso Monnapula, a master’s student in the Division of Consumer Science, is experimenting with bacterial cellulose, which is produced as a by-product in the fermentation process when making kombucha. Her goal is to determine its efficacy as a possible sustainable textile alternative for use in the apparel industry.

She says finding this textile alternative was initially the result of pure curiosity. “My brother brews kombucha, so we always wondered in what other ways this fascinating mass of cellulose could be used.”

“It was upon further research that we discovered that there actually is more to it – from within the textile industry, biomedical and tissue engineering disciplines, paper and audio speaker manufacturing, to even the food industry,” states Monnapula.

She had a greater inclination towards its use in the textile industry and presented the idea to her supervisor, Dr Jana Vermaas, Lecturer in the Department of Sustainable Food Systems and Development. “From there it was all systems go,” remarks Monnapula. 

The interesting process of growing this textile entails brewing tea (black, green, or rooibos tea can be used for this purpose) and adding sugar, vinegar, or previously brewed kombucha to maintain a favourable pH level. “One then inoculates the sweetened tea with a starter culture of acetic acid bacteria and yeasts, also known as SCOBY (symbiotic culture of bacteria and yeasts). It is then left for two to four weeks under specific conditions, during which the fermentation process takes place. In this period, the cellulose gradually starts to form on the liquid’s surface,” explains Monnapula, who was assisted by her co-supervisor, Prof Celia Hugo from the Department of Microbiology and Biochemistry. 

Vegan leather

The process of making bacterial cellulose accounts for the many benefits of this leather-like textile. “The process and its aftermath are significantly less detrimental to the environment than most commercial textiles produced today. It is known that the textile industry is characterised by the excessive usage of chemicals, water, energy, and the generation of toxic effluent that is not always disposed of correctly, thereby affecting human, vegetal and animal well-being. Moreover, it eliminates animal cruelty, and in relation to real leather, it will also be more available and less expensive.”

“Secondly,” she states, “bacterial cellulose is biodegradable, which is one way of contributing towards a circular economy in the textile industry, while moving away from the traditional linear economy we know today.”

Within the apparel industry, this textile, which is mostly suitable for accessories, can be used to make products that are typically made of leather. For instance, bags, jackets, shoes, and bucket hats. 

From kombucha to leather-like textile
Samples of the new textile made from Kambucha. Photo: Leonie Bolleurs 

 

Versatile use

She states that according to their knowledge, the bacterial cellulose has not yet been grown in South Africa or Africa. However, it has been extensively researched in America and Europe. “There have been several experiments to make biodegradable packaging, facial masks in the cosmetics industry, sausage casings, and fruit rolls – and interestingly enough – it can even be enjoyed as a native Philippine dessert known as nata de coco. This goes to show how versatile it is,” she says.

Monnapula says there is still plenty of room for improvement and further development before reaching a point where she can introduce her work as a contender in the South African market. For instance, the waterproof capability of the textile is yet to be perfected. “More research is also necessary to enhance its hydrophobic and decreasing its hydrophilic properties.”

She is also of the opinion that further dyeing, using environmentally friendly methods and natural dyes to obtain a wider variety of colours, is necessary. 

Penetrating the market

Once it is ready, this textile will be a marketable product that can be manufactured for commercial use. “A few European start-up companies have recently managed to penetrate the market and introduce apparel made from bacterial cellulose. I believe that upon further development and modifications, we can eventually follow suit,” says Monnapula.

The bacterial cellulose textile was evaluated in the UFS Sensory Lab, a facility mostly used to test food products. Liezl van der Walt, Sensory Lab Manager, states that the Sensory Lab plays a crucial role in determining the consumer acceptance of new products as well as how the product can be improved. She believes that the textile project was just the beginning of many more textile-related sensory panels to take place. 


Within the apparel industry, this textile can be used to make products that are typically made of leather, including bags, jackets, shoes, and bucket hats. – Matseliso Monnapula

 


News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept